Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Single Dose SHR4640 in Healthy Male Volunteers
NCT03015948Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ruzinurad in gout and hyperuricemia (5 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Safety and Tolerability Assessment at 11 days. Started Sep 2016; status: completed.
02
Drugs
ruzinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT03015948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015948.